Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Congress Will Look To “Hesitant” FDA To Regulate Biosimilars – Former HHS Deputy

This article was originally published in The Pink Sheet Daily

Executive Summary

Follow-on biologics, and their eventual road to approval, were weighty discussion topics on the opening day of the BIO CEO conference.

You may also be interested in...



Ranbaxy’s First Biosimilar Target Will Be Amgen’s Neupogen

Ranbaxy is partnered with another Indian drug maker, Zenotech, in its foray into biosimilar development.

HHS’ Azar Departing To Explore Private Sector Opportunities

Deputy Sectary to leave after five and a half years with department; no successor announced.

Hospira, Stada Collaboration To Yield Biosimilar EPO In The EU Ahead Of U.S.

Hospira obtains exclusive distribution rights for Bioceuticals erythropoietin in the EU and will be solely responsible for U.S. development.

Related Content

Topics

UsernamePublicRestriction

Register

OM017181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel